$CW

Watts John C sold $154K of CW

Watts John C (EVP & Chief Growth Officer) sold 200 shares of CURTISS WRIGHT CORP (CW) at $770.56 ($0.15M total) on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Watts John C
Published Jun 15, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 15, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CW
Neutral
high confidence
Mentioned
$CW
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CWNeutralLow
01

Why it matters

This updates insider activity records and may influence short-term sentiment/flow optics, but it does not introduce new operating, financial, or regulatory information.

02

Market read

Primarily a sentiment/positioning datapoint; likely low impact on trading decisions absent additional catalysts.

03

What to watch

The article provides only the sale size and plan type; it does not include any concurrent buys, option exercises, or broader corporate news that would change the fundamental outlook.

Relevance 3/10Novelty 5/10Timing: Filed same day (2026-06-15) for an insider sale at $770.56/share

Background

The article is a primary-source SEC Form 4 insider transaction disclosure (open-market sale) for Curtiss-Wright’s EVP & Chief Growth Officer.

Company-level read

Ticker impact

$CWNeutralHigh confidence
Context

SEC Form 4 shows Watts John C (EVP & Chief Growth Officer) sold 200 shares of Curtiss-Wright at $770.56 on 2026-06-15 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4; any reaction would be short-lived unless paired with other catalysts.

Evidence & confidence

The filing is an open-market sale by an officer and explicitly states a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

No sector-level read-through; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with management’s view of near-term valuation or liquidity needs; traders may still monitor for clustering with other negative signals.

Key entities

  • Curtiss Wright Corp

    Issuer of the Form 4 insider transaction; officer sale disclosed on 2026-06-15.

  • Watts John C

    EVP & Chief Growth Officer who sold 200 shares under a pre-arranged Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CWMed

Curtiss-Wright Slides As Investors Question CEO Handoff

Curtiss-Wright (CW) shares fell as investors reacted to a planned leadership transition, with the current COO set to become CEO in 2027. Concerns about strategic continuity and execution risk were raised, despite the company's strong financial position and growth prospects. Quarterly results may be volatile due to cash conversion and supply chain pressures.

$CWMedAI 8/10

Why is Curtiss-Wright stock sliding today?

Curtiss-Wright stock fell 4.0% after announcing CEO Lynn M. Bamford will transition to Executive Chair, with COO Kevin M. Rayment succeeding in 2027. The change introduced strategic uncertainty, and the stock is near a 52-week low of $544.64, below its high of $808.16. The ex-dividend date is also approaching, adding to the pressure.

$CWMed

CW Initiated Coverage by Guggenheim -- Rating Upgraded to Buy

Guggenheim initiated coverage on Curtiss-Wright (CW) with a 'Buy' rating and a $786.00 price target. The stock is currently trading at $551.21, which is 24.3% above its GF Value™ of $443.58, indicating overvaluation. CW has a GF Score™ of 94/100, reflecting strong performance in growth and profitability, but a valuation rank of 5/10. Insider activity shows net selling of $705,928 over the last three months.

$CWMed

Curtiss Wright (CW) Wins New Defense Work, Is The Stock Cheap After The Selloff?

Curtiss-Wright (CW) secured $40M in contracts for the U.S. Army's air defense system. Its stock is down 24.3% over 30 days, but up 17.8% over 1 year. Analysts debate its valuation, with some seeing it as undervalued at $566.75, citing strong backlog growth and growth projections. The company trades at a P/E of 38.7x, lower than peers but higher than its own fair ratio of 24.8x.

$CWMed

Piper Sandler initiates Curtiss-Wright stock at neutral on valuation

Piper Sandler initiated coverage on Curtiss-Wright (NYSE:CW) with a Neutral rating and $665 price target, citing valuation concerns. The company reported Q2 earnings beating EPS estimates but missing on revenue. Curtiss-Wright's order book is up 12% YTD, and it raised its full-year outlook. Piper Sandler notes the stock's multiple expansion and potential overvaluation.

$CWHighAI 8/10

Curtiss-Wright reports strong Q2 2026 results and raises full-year guidance across defense, nuclear and industrial markets

Curtiss-Wright reported Q2 2026 sales of $924M, adjusted EPS of $3.72, and adjusted operating margin of 19.4%, all above expectations. The company raised full-year guidance to 8-9% sales growth and 14-16% EPS growth, with free cash flow outlook at $585M-$605M. New orders increased 8% YoY to $1.1B, and backlog reached $4.5B, up 10% from year-end 2025.